Hims & Hers Expands Portfolio with FDA-Approved Weight Management Drugs

Hims & Hers pivots from compounded drugs to FDA-approved GLP-1s from Novo Nordisk, launching a new subscription program as it builds on strong 2025 financial results.

The telehealth platform Hims & Hers has significantly broadened its weight management treatment options. In a strategic shift, the company now offers FDA-approved GLP-1 medications from Novo Nordisk directly through its service, effective March 26, 2026. The newly available branded products include Wegovy injections across multiple dosage strengths and Ozempic pens for qualifying patients.

A Strategic Pivot from Compounded Formulas

This expansion signals a notable change in direction. Previously, the company's weight management segment relied heavily on compounded GLP-1 preparations—custom-mixed formulations produced outside standard regulatory pathways. By partnering directly with Novo Nordisk, Hims & Hers is transitioning its core offering toward a wider selection of officially sanctioned brand-name pharmaceuticals.

Analysts note this move likely enhances treatment reliability and could improve patient adherence. However, the increased reliance on third-party suppliers may pressure gross margins over time. Pricing for the medications starts at $149 per month. Alongside this, the company launched a new comprehensive weight loss subscription program. The introductory month is priced at $39, followed by a $149 monthly fee, which includes nutritional guidance, physician access, and community support features.

Financial Performance Provides Solid Foundation

The company's fiscal 2025 results demonstrate a strong operational position from which to execute this strategy. Revenue climbed 59% to approximately $2.35 billion, with net income reaching $128 million. Adjusted EBITDA for the year was $318 million. The platform ended 2025 with over 2.5 million subscribers, reflecting a 13% year-over-year increase.

Looking ahead, management has provided 2026 revenue guidance in the range of $2.7 to $2.9 billion. Projected adjusted EBITDA is forecast between $300 million and $375 million. Market observers will be watching closely to see if the new product strategy's potential margin pressures are offset by accelerated subscriber growth, with the upcoming quarterly results expected to provide early indicators.